Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Deferred Revenue (2021 - 2025)

Autolus Therapeutics' Current Deferred Revenue history spans 5 years, with the latest figure at $7.6 million for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 96.26% year-over-year to $7.6 million; the TTM value through Sep 2025 reached $7.6 million, down 96.26%, while the annual FY2022 figure was $35.0 million, 25.53% down from the prior year.
  • Current Deferred Revenue reached $7.6 million in Q3 2025 per AUTL's latest filing, up from $2.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $203.4 million in Q3 2024 to a low of $2.1 million in Q2 2025.
  • Average Current Deferred Revenue over 5 years is $91.7 million, with a median of $47.0 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 44.46% in 2024, then plummeted 98.93% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $47.0 million in 2021, then decreased by 25.53% to $35.0 million in 2022, then skyrocketed by 302.29% to $140.8 million in 2023, then surged by 44.46% to $203.4 million in 2024, then crashed by 96.26% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Current Deferred Revenue are $7.6 million (Q3 2025), $2.1 million (Q2 2025), and $4.7 million (Q1 2025).